{"database": "lobbying", "table": "lobbying_activities", "rows": [[2772484, "b9f69c38-63e2-4c4a-8370-231610804ab0", "Q1", "THE NICKLES GROUP, LLC", 293335, "AMGEN", 2022, "first_quarter", "GOV", "H.R. 5376, The Build Better Back Act and issue regarding drug pricing. Issues regarding ESRD payments. H.R. 3517, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021. Monitored the FDA user fee agreements.", "HOUSE OF REPRESENTATIVES", 50000, null, 0, 0, "2022-04-12T17:46:48-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2772484"], "units": {}, "query_ms": 0.4162190016359091, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}